PHARMACEUTICAL COMPOSITION CONTAINING 1-{2-[(3S,4R)-1-{[(3R,4R)-1-CYCLOPENTYL-3-FLUORO-4-(4-METHOXYPHENYL)PYRROLIDINE-3-YL]CARBONYL}-4-(METHOXYMETHYL)PYRROLIDINE-3-YL]-5-(TRIFLUOROMETHYL)PHENYL}PIPERIDINE-4-CARBOXYLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT OR CO-CRYSTAL THEREOF

Title:

Document Type and Number:

WIPO Patent Application WO/2024/029599

Kind Code:

A1

Abstract:

Provided is a pharmaceutical composition containing, as an active ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidine-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid (compound A) or a pharmaceutically acceptable salt or co-crystal thereof, wherein the content of the compound A is at least 30 wt% based on the total weight of the pharmaceutical composition and the pharmaceutical composition is preferably obtained by a production method which includes a granulation step for obtaining a granulated product by spraying a binding liquid, which includes the compound A or a pharmaceutically acceptable salt or co-crystal thereof and a binding agent, onto a powder, which includes the compound A or a pharmaceutically acceptable salt or co-crystal thereof, in a fluidized bed granulator.

More Like This:

JP5439381	Piperidinyl and piperazinyl regulators of γ-secretase
JP7025432	Pyran derivative as an inhibitor of CYP11A1 (cytochrome P450 monooxygenase 11A1)
WO/2014/012511	N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF

Inventors:

SUZUKI AKIHIRO (JP)
TOKUDA TAKAYUKI (JP)
UEHARA TOMOYUKI (JP)

Application Number:

PCT/JP2023/028459

Publication Date:

February 08, 2024

Filing Date:

August 03, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

MITSUBISHI TANABE PHARMA CORP (JP)

International Classes:

A61K31/454; A61K9/20; A61K9/48; A61K47/38; A61P1/04; A61P1/16; A61P7/00; A61P9/00; A61P9/10; A61P13/12; A61P17/00; A61P17/04; A61P17/14; A61P19/02; A61P19/06; A61P25/00; A61P25/04; A61P27/02; A61P29/00; A61P31/00; A61P31/04; A61P31/18; A61P35/00; A61P37/06; A61P43/00

Domestic Patent References:

WO2021251452A1	2021-12-16
WO2020138481A1	2020-07-02
WO2015182723A1	2015-12-03

Foreign References:

JP6959478B1	2021-11-02
JP2017122056A	2017-07-13

Attorney, Agent or Firm:

IP FIRM SHUWA (JP)

Download PDF:

View/Download PDF PDF Help

Previous Patent: COMPOSITION FOR IMPROVING OR MAINTAINING MUSCLE AMOUNT OR MUSCLE STRENGTH

Next Patent: SKIN CONDITION ESTIMATING METHOD